Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy

We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895

Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research